{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T04:14:53Z","timestamp":1745381693894,"version":"3.40.4"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2025,1,29]],"date-time":"2025-01-29T00:00:00Z","timestamp":1738108800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,1,29]],"date-time":"2025-01-29T00:00:00Z","timestamp":1738108800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Hematol"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1007\/s12185-025-03933-1","type":"journal-article","created":{"date-parts":[[2025,1,29]],"date-time":"2025-01-29T18:18:21Z","timestamp":1738174701000},"page":"658-669","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Response to initial treatment with glucocorticoids in TAFRO syndrome and implications for secondary treatment"],"prefix":"10.1007","volume":"121","author":[{"given":"Ryutaro","family":"Tominaga","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kento","family":"Umino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seina","family":"Honda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daizo","family":"Yokoyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atsuto","family":"Noguchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuka","family":"Furuki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shunsuke","family":"Koyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rui","family":"Murahashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hirotomo","family":"Nakashima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuki","family":"Hyodo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shin-ichiro","family":"Kawaguchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yumiko","family":"Toda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daisuke","family":"Minakata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masahiro","family":"Ashizawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chihiro","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kaoru","family":"Hatano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuya","family":"Sato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ken","family":"Ohmine","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shin-ichiro","family":"Fujiwara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4866-9307","authenticated-orcid":false,"given":"Yoshinobu","family":"Kanda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,1,29]]},"reference":[{"key":"3933_CR1","first-page":"320","volume":"51","author":"K Takai","year":"2010","unstructured":"Takai K, Nikkuni K, Shibuya H, Hashidate H. Thrombocytopenia with mild bone marrow fibrosis accompanied by fever, pleural effusion, ascites and hepatosplenomegaly. Rinsho Ketsueki. 2010;51:320\u20135.","journal-title":"Rinsho Ketsueki"},{"issue":"111","key":"3933_CR2","first-page":"155","volume":"2020","author":"Y Masaki","year":"2019","unstructured":"Japanese TAFRO Syndrome Research Team, Masaki Y, Kawabata H, Takai K, Tsukamoto N, Fujimoto S, et al. updated diagnostic criteria and disease severity classification for TAFRO syndrome. Int J Hematol. 2019;2020(111):155\u20138.","journal-title":"Int J Hematol"},{"key":"3933_CR3","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1007\/s12185-016-1979-1","volume":"103","author":"Y Masaki","year":"2016","unstructured":"Masaki Y, Kawabata H, Takai K, Kojima M, Tsukamoto N, Ishigaki Y, et al. Proposed diagnostic criteria, disease severity classification and treatment strategy for TAFRO syndrome, 2015 version. Int J Hematol. 2016;103:686\u201392.","journal-title":"Int J Hematol"},{"key":"3933_CR4","doi-asserted-by":"publisher","first-page":"e135031","DOI":"10.1172\/jci.insight.135031","volume":"5","author":"RAL Pai","year":"2020","unstructured":"Pai RAL, Japp AS, Gonzalez M, Rasheed RF, Okumura M, Arenas D, et al. Type I IFN response associated with mTOR activation in the TAFRO subtype of idiopathic multicentric Castleman disease. JCI Insight. 2020;5:e135031.","journal-title":"JCI Insight"},{"key":"3933_CR5","doi-asserted-by":"publisher","first-page":"1194","DOI":"10.1111\/bjh.17993","volume":"196","author":"N Abe","year":"2022","unstructured":"Abe N, Kono M, Ohnishi N, Sato T, Tarumi M, Yoshimura M, et al. Glycogen synthase kinase 3\u03b2\/CCR6-positive bone marrow cells correlate with disease activity in multicentric Castleman disease-TAFRO. Br J Haematol. 2022;196:1194\u2013204.","journal-title":"Br J Haematol"},{"key":"3933_CR6","doi-asserted-by":"publisher","first-page":"27","DOI":"10.2169\/internalmedicine.9622-22","volume":"62","author":"Y Masaki","year":"2023","unstructured":"Masaki Y, Ueda Y, Yanagisawa H, Arita K, Sakai T, Yamada K, et al. TAFRO syndrome: a disease requiring immediate medical attention. Intern Med. 2023;62:27\u201332.","journal-title":"Intern Med"},{"key":"3933_CR7","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.1002\/ajh.26292","volume":"96","author":"Y Nishimura","year":"2021","unstructured":"Nishimura Y, Fajgenbaum DC, Pierson SK, Iwaki N, Nishikori A, Kawano M, et al. Validated international definition of the thrombocytopenia, anasarca, fever, reticulin fibrosis, renal insufficiency, and organomegaly clinical subtype (TAFRO) of idiopathic multicentric CASTLEMAN disease. American J Hematol. 2021;96:1241\u201352.","journal-title":"American J Hematol"},{"key":"3933_CR8","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1002\/ajh.25554","volume":"94","author":"S Fujimoto","year":"2019","unstructured":"Fujimoto S, Sakai T, Kawabata H, Kurose N, Yamada S, Takai K, et al. Is TAFRO syndrome a subtype of idiopathic multicentric Castleman disease? Am J Hematol. 2019;94:975\u201383.","journal-title":"Am J Hematol"},{"key":"3933_CR9","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1038\/bmt.2012.244","volume":"48","author":"Y Kanda","year":"2013","unstructured":"Kanda Y. Investigation of the freely available easy-to-use software \u2018EZR\u2019 for medical statistics. Bone Marrow Transplant. 2013;48:452\u20138.","journal-title":"Bone Marrow Transplant"},{"key":"3933_CR10","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1007\/s12185-021-03159-x","volume":"114","author":"H Kawabata","year":"2021","unstructured":"Kawabata H, Fujimoto S, Sakai T, Yanagisawa H, Kitawaki T, Nara K, et al. Patient\u2019s age and d-dimer levels predict the prognosis in patients with TAFRO syndrome. Int J Hematol. 2021;114:179\u201388.","journal-title":"Int J Hematol"},{"key":"3933_CR11","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1080\/24725625.2020.1717747","volume":"4","author":"Y Yamaguchi","year":"2020","unstructured":"Yamaguchi Y, Maeda Y, Shibahara T, Nameki S, Nakabayashi A, Komuta K, et al. Recovery from prolonged thrombocytopenia in patients with TAFRO syndrome: case series and literature review. Mod Rheumatol Case Rep. 2020;4:302\u20139.","journal-title":"Mod Rheumatol Case Rep"},{"key":"3933_CR12","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1111\/bjh.19279","volume":"204","author":"AI Rubenstein","year":"2024","unstructured":"Rubenstein AI, Pierson SK, Shyamsundar S, Bustamante MS, Gonzalez MV, Miller ID, et al. Immune-mediated thrombocytopenia and IL-6-mediated thrombocytosis observed in idiopathic multicentric Castleman disease. Br J Haematol. 2024;204:921\u201330.","journal-title":"Br J Haematol"},{"key":"3933_CR13","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.2169\/internalmedicine.9484-17","volume":"57","author":"Y Takayama","year":"2018","unstructured":"Takayama Y, Kubota T, Ogino Y, Ohnishi H, Togitani K, Yokoyama A. TAFRO syndrome with disseminated intravascular coagulation successfully treated with tocilizumab and recombinant thrombomodulin. Intern Med. 2018;57:1291\u20136.","journal-title":"Intern Med"},{"key":"3933_CR14","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1186\/s12882-019-1574-9","volume":"20","author":"Y Nagayama","year":"2019","unstructured":"Nagayama Y, Yamano M, Yagame M, Nariyama T, Takahashi M, Kawamoto M, et al. TAFRO syndrome as a cause of glomerular microangiopathy: a case report and literature review. BMC Nephrol. 2019;20:375.","journal-title":"BMC Nephrol"},{"key":"3933_CR15","doi-asserted-by":"publisher","first-page":"747678","DOI":"10.3389\/fmed.2021.747678","volume":"8","author":"M Nagai","year":"2021","unstructured":"Nagai M, Uchida T, Yamada M, Komatsu S, Ota K, Mukae M, et al. TAFRO syndrome in a kidney transplant recipient that was diagnosed on autopsy: a case report. Front Med. 2021;8:747678.","journal-title":"Front Med"},{"key":"3933_CR16","doi-asserted-by":"publisher","first-page":"1266187","DOI":"10.3389\/fimmu.2023.1266187","volume":"14","author":"H Sato","year":"2023","unstructured":"Sato H, Kanno A, Sato M, Endo A, Ito H, Ohara T, et al. Case report: a case of TAFRO syndrome with severe and prolonged thrombocytopenia: diagnostic pitfalls. Front Immunol. 2023;14:1266187.","journal-title":"Front Immunol"},{"key":"3933_CR17","doi-asserted-by":"publisher","first-page":"e8216","DOI":"10.1097\/MD.0000000000008216","volume":"96","author":"M Tanaka","year":"2017","unstructured":"Tanaka M, Tsujimoto H, Yamamoto K, Shimoda S, Oka K, Takeoka H. Clinicopathological features of progressive renal involvement in TAFRO syndrome: a case report and literature review. Medicine. 2017;96:e8216.","journal-title":"Medicine"},{"key":"3933_CR18","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.2169\/internalmedicine.0116-17","volume":"57","author":"H Tsurumi","year":"2018","unstructured":"Tsurumi H, Fujigaki Y, Yamamoto T, Iino R, Taniguchi K, Nagura M, et al. Remission of refractory ascites and discontinuation of hemodialysis after additional rituximab to long-term glucocorticoid therapy in a patient with TAFRO syndrome. Intern Med. 2018;57:1433\u20138.","journal-title":"Intern Med"},{"key":"3933_CR19","doi-asserted-by":"publisher","first-page":"2861","DOI":"10.2169\/internalmedicine.55.6455","volume":"55","author":"E Ohya","year":"2016","unstructured":"Ohya E, Mizutani M, Sakaguchi H, Sekine T. Diffuse large B-cell lymphoma during corticosteroid therapy for TAFRO syndrome. Intern Med. 2016;55:2861\u20137.","journal-title":"Intern Med"},{"key":"3933_CR20","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1007\/s12185-020-03008-3","volume":"113","author":"S Fujimoto","year":"2021","unstructured":"Fujimoto S, Kawabata H, Sakai T, Yanagisawa H, Nishikori M, Nara K, et al. Optimal treatments for TAFRO syndrome: a retrospective surveillance study in Japan. Int J Hematol. 2021;113:73\u201380.","journal-title":"Int J Hematol"},{"key":"3933_CR21","doi-asserted-by":"publisher","first-page":"175","DOI":"10.3960\/jslrt.19021","volume":"59","author":"Y Masaki","year":"2019","unstructured":"Masaki Y, Kawabata H, Fujimoto S, Kawano M, Iwaki N, Kotani T, et al. Epidemiological analysis of multicentric and unicentric Castleman disease and TAFRO syndrome in Japan. JCEH. 2019;59:175\u20138.","journal-title":"JCEH"}],"container-title":["International Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-025-03933-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12185-025-03933-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-025-03933-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,22]],"date-time":"2025-04-22T10:48:31Z","timestamp":1745318911000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12185-025-03933-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,29]]},"references-count":21,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["3933"],"URL":"https:\/\/doi.org\/10.1007\/s12185-025-03933-1","relation":{},"ISSN":["0925-5710","1865-3774"],"issn-type":[{"type":"print","value":"0925-5710"},{"type":"electronic","value":"1865-3774"}],"subject":[],"published":{"date-parts":[[2025,1,29]]},"assertion":[{"value":"4 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 January 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 January 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 January 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"D. Minakata has received payments for lectures from Bristol Myers Squibb and Janssen Pharmaceutical K.K. S. Fujiwara has received payments for lectures from Bristol Myers Squibb. K. Ohmine has received research grants from Takara Biomedical Inc. Y. Kanda has received payment for lectures from Pfizer Japan Inc., Sumitomo Pharma Co., Ltd., Novartis Pharma K.K., Sanofi K.K., CHUGAI PHARMACEUTICAL CO., LTD., SymBio Pharmaceuticals Limited, Bristol Myers Squibb, Janssen Pharmaceutical K.K, ASAHI KASEI PHARMA CORPORATION, MSD K.K., Astellas Pharma Inc. and Kyowa Kirin Co., Ltd. Y. Kanda has received research grants from Celgene Corporation, Sumitomo Pharma Co., Ltd., Kyowa Kirin Co., Ltd., CHUGAI PHARMACEUTICAL CO., LTD., and Eisai Co., Ltd. These are not related to the current study. Y. Kanda is involved in the editing of International Journal of Hematology as an associate editor. The other authors have no conflicts of interest to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}